Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic KRAS G12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers
Edurne Mugarza, Febe van Maldegem, Jesse Boumelha, et al.
Science Advances (2022) Vol. 8, Iss. 29
Open Access | Times Cited: 86

Showing 1-25 of 86 citing articles:

Drugging KRAS: current perspectives and state-of-art review
Kaushal Parikh, Giuseppe Luigi Banna, Stephen V. Liu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 83
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Itziar Otano, Álvaro C. Ucero, Jon Zugazagoitia, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 3, pp. 143-159
Closed Access | Times Cited: 82
Exploiting the therapeutic implications of KRAS inhibition on tumor immunity
Míriam Molina‐Arcas, Julian Downward
Cancer Cell (2024) Vol. 42, Iss. 3, pp. 338-357
Open Access | Times Cited: 46
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 24
An Immunogenic Model of KRAS-Mutant Lung Cancer Enables Evaluation of Targeted Therapy and Immunotherapy Combinations
Jesse Boumelha, Sophie de Carné Trécesson, Emily K. Law, et al.
Cancer Research (2022) Vol. 82, Iss. 19, pp. 3435-3448
Open Access | Times Cited: 56
Mutant KRAS Drives Immune Evasion by Sensitizing Cytotoxic T‐Cells to Activation‐Induced Cell Death in Colorectal Cancer
Huashan Liu, Zhenxing Liang, Sijing Cheng, et al.
Advanced Science (2023) Vol. 10, Iss. 6
Open Access | Times Cited: 28
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Guowei Yin, Jing Huang, Johnny Petela, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 27
Cancer immune evasion through KRAS and PD-L1 and potential therapeutic interventions
Alex Watterson, Matthew A. Coelho
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 23
Exploiting Tertiary Lymphoid Structures to Stimulate Antitumor Immunity and Improve Immunotherapy Efficacy
Giulia Petroni, Serena Pillozzi, Lorenzo Antonuzzo
Cancer Research (2024) Vol. 84, Iss. 8, pp. 1199-1209
Open Access | Times Cited: 12
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer
Haniel A. Araújo, Ximo Pechuan-Jorge, Teng Zhou, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2183-2208
Closed Access | Times Cited: 10
MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer
Sílvia Casacuberta‐Serra, Íñigo González-Larreategui, Daniel Capitán-Leo, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 8
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial
Yuankai Shi, Jian Fang, Ligang Xing, et al.
Nature Medicine (2025)
Closed Access | Times Cited: 1
Immunotherapy in Oncogene-Addicted NSCLC: Evidence and Therapeutic Approaches
Lorenzo Foffano, Elisa Bertoli, Martina Bortolot, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 583-583
Open Access | Times Cited: 1
Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung
Eduardo Moreo, Aitor Jarit-Cabanillas, Iñaki Robles‐Vera, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 19
Strategies for Heating Up Cold Tumors to Boost Immunotherapies
Daniel J. Zabransky, Mark Yarchoan, Elizabeth M. Jaffee
Annual Review of Cancer Biology (2023) Vol. 7, Iss. 1, pp. 149-170
Closed Access | Times Cited: 16
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Yuko Oya, Kazuyoshi Imaizumi, Tetsuya Mitsudomi
Lung Cancer (2024) Vol. 194, pp. 107886-107886
Open Access | Times Cited: 7
Base editing screens define the genetic landscape of cancer drug resistance mechanisms
Matthew A. Coelho, Magdalena E. Strauß, Alex Watterson, et al.
Nature Genetics (2024) Vol. 56, Iss. 11, pp. 2479-2492
Open Access | Times Cited: 7
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity
Emily K. Kleczko, Trista K. Hinz, Teresa T. Nguyen, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 14
MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer
Juan J. Alburquerque-Béjar, Pablo Navajas-Chocarro, Maria Saigí, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 4, pp. 101006-101006
Open Access | Times Cited: 14
Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy
Jesse Boumelha, Míriam Molina‐Arcas, Julian Downward
Clinical Cancer Research (2023) Vol. 29, Iss. 24, pp. 5012-5020
Open Access | Times Cited: 14
Prospective virtual screening combined with bio-molecular simulation enabled identification of new inhibitors for the KRAS drug target
Amar Ajmal, Hind A. Alkhatabi, Roaa M. Alreemi, et al.
BMC Chemistry (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 5
CRISPR-Cas9 screening identifies KRAS-induced COX-2 as a driver of immunotherapy resistance in lung cancer
Jesse Boumelha, Andrea de Castro, Nourdine Bah, et al.
Cancer Research (2024) Vol. 84, Iss. 14, pp. 2231-2246
Open Access | Times Cited: 5
Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysis
Tian Tian, Yanying Li, Juan Li, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 4, pp. 861-874
Open Access | Times Cited: 5
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
Wei Ye, Lu Xin, Yue Qiao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 3, pp. 189108-189108
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top